Selected article for: "cell culture and plaque assay"
Author: Risner, Kenneth H.; Tieu, Katie V.; Wang, Yafei; Bakovic, Allison; Alem, Farhang; Bhalla, Nishank; Nathan, Steven; Conway, Daniel E.; Macklin, Paul; Narayanan, Aarthi
Title: Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture
  • Cord-id: 67t2q5ud
  • Document date: 2020_8_13
    • ID: 67t2q5ud
    Snippet: In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A screen of 19 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The screen identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that we
    Document: In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A screen of 19 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The screen identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that were able to inhibit SARS-CoV-2 infection. Confocal microscopy with over expressed S protein demonstrated that Maraviroc reduced the extent of S-protein mediated cell fusion as observed by fewer multinucleate cells in drug-treated cells. Mathematical modeling of drug-dependent viral multiplication dynamics revealed that prolonged drug treatment will exert an exponential decrease in viral load in a multicellular/tissue environment. Taken together, the data demonstrate that Maraviroc, Fingolimod, Atorvastatin and Nitazoxanide inhibit SARS-CoV-2 in cell culture.

    Search related documents:
    Co phrase search for related documents
    • abl kinase and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • abl kinase and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • abl kinase inhibitor and acute respiratory: 1, 2, 3
    • abl kinase inhibitor and acute respiratory syndrome: 1, 2, 3
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute respiratory virus: 1, 2, 3, 4, 5
    • absence presence and addition step: 1, 2
    • absence presence and additional role: 1, 2
    • absence presence and additional role play: 1
    • actin cytoskeleton and acute respiratory: 1
    • actin cytoskeleton and acute respiratory distress syndrome: 1
    • actin cytoskeleton and acute respiratory syndrome: 1
    • actin cytoskeleton and additional role: 1
    • acute respiratory and addition step: 1, 2, 3
    • acute respiratory and additional complication: 1, 2, 3
    • acute respiratory and additional inhibitor: 1, 2, 3
    • acute respiratory and additional method: 1, 2, 3